The Clostridia Technology Company

CHAIN Biotechnology Ltd was founded by Dr Edward Green in 2014 to develop new Clostridium-based microbial technology for high value healthcare products. CHAIN produces novel live biotherapeutic products (LBPs) for chronic gut-related diseases, such as Inflammatory Bowel Disease (IBD).

At the heart of CHAIN’s unique therapeutic platform is a suite of underpinning technologies including a Clostridia culture collection, a proprietary set of plasmid vectors, synthetic biology tools for advanced metabolic engineering, and an advanced in-vivo delivery mechanism using Clostridium.

Anaerobic Clostridia bacteria, naturally present in healthy human guts, produce short-chain fatty acids and antimicrobial peptides which aid the immune system as part of a healthy gut microbiome. Disturbance of the gut microbiome (dysbiosis) may result in damage to both mucosal and epithelial cell membranes resulting in chronic diseases like IBD, but also colon cancer, diabetes, obesity, and auto-immune disorders.

CHAIN has assembled an experienced team of managers and expert scientific researchers. The Company has adopted a differentiated and capital efficient business model leveraging considerable academic firepower from University collaborators.

CHAIN is based at Imperial College, London, and the core technical team is embedded within the Synthetic Biology Research Centre at the University of Nottingham. CHAIN is ideally placed for collaboration with clinicians and medical researchers from Imperial College and the Universities of Nottingham, Leeds and Cardiff.

CHAIN is on LinkedIn, Twitter, and we can be contacted here.

Management Team